Please login to the form below

Not currently logged in
Email:
Password:

lymphoma

This page shows the latest lymphoma news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in testing for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), as

Latest news

More from news
Approximately 48 fully matching, plus 289 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's Tyrosine Kinase.

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma.

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two sessions.

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... relapsed or refractory aggressive CD19

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics